The FTD Disorders Registry was recently featured at #CTAD2025 in San Diego! Dr. Shana Dodge presented a poster showing how the Registry is helping accelerate clinical trial recruitment.
Read more: ftdregistry.org/press/ftd-di...
The EVOKE trials found that semaglutide, the GLP-1 drug behind several popular diabetes and weight loss medications, did not meaningfully slow cognitive decline in people with Alzheimer’s disease.
Explore this research and more news from #CTAD2025. https://bit.ly/48KgAxG
New study results indicate that lifestyle changes can protect aging brains. The U.S. POINTER study tested whether a structured, healthy lifestyle program could protect cognitive function in at-risk older adults. The answer is YES.
Explore this news and more from #CTAD2025: https://bit.ly/4pTAgoa
Once again, we participate at the #CTAD2025!
This year, @gsalvado.bsky.social gave an oral presentation about the use of blood-based biomarkers and their key role in the clinical trials field.
www.barcelonabeta.org/en/news/news...
Three ancillary studies to the U.S. POINTER trial collectively demonstrated that a structured 2-year lifestyle intervention for older adults at increased risk of cognitive decline led to better overall health. #CTAD2025
www.medpagetoday.com/meetingcover...
Some preliminary data on CSF and plasma biomarkers of disease activity and neuroinflammation from the two evoke trials with oral semaglutide #Alzheimersdisease #CTAD2025 sciencehub.novonordisk.com/congresses/c... 🧪
Attending #CTAD2025 this week? Stop by our poster P407 to learn more about the FTD Disorders Registry. #endFTD
At #CTAD2025, Novo Nordisk shared new phase 3 results from Evoke/Evoke+ trials, offering important insights that underscore a critical shift toward the next era of drug development, which will target the underlying biology of this complex disease.
bit.ly/4iMH1WH
New data presented at #CTAD2025 📊
Etalanetug cut tau pathology biomarkers fast in dominantly inherited #Alzheimer
Key Changes:
🧬 CSF eMTBR-tau243 ↓ 62%
🩸 Plasma eMTBR-tau243 ↓ 78%
Read more here: www.neurologylive.com/view/ctad-po...
#AD #Neurology #TAU #BrainHealth #Conference #Coverage #Neuro
It's a great day in San Diego for Day 2 of #CTAD2025! We look forward to sessions exploring the latest science. This afternoon, we will hold our working lunch on Driving Innovation where experts will discuss policy alignment with breakthroughs in biomarkers, AI, and precision medicine.
GLP-1 therapies are attracting attention and traction in Alzheimer’s research, but vascular co-pathology remains a critical factor in trial design. In the run-up to #CTAD2025, IXICO CSO Robin Wolz explains why vascular phenotyping matters.
Read more: ixico.com/news-and-res...
We’re heading to #CTAD2025 next week in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
Let’s connect at #CTAD2025 (Dec 1–4)
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
We’re headed to #CTAD2025 in San Diego!
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
